Chemical chaperone therapy:a new molecular therapeutic approach to neurogenetic diseases
Suzuki, Y.
No to Hattatsu 42(2): 134-137
2010
ISSN/ISBN: 0029-0831 PMID: 23858598 Document Number: 638022
Document emailed within 1 workday
Related Documents
Pipas, J.M. 1998: Molecular chaperone function of the SV40 large T antigen Developments in Biological Standardization 94: 313-319Mizobata, T.; Kawata, Y. 2001: Dynamic conformational changes which support the function of molecular chaperone GroE Seikagaku. Journal of Japanese Biochemical Society 73(5): 361-366
Surin, A.K.; Kotova, N.V.; Marchenkova, S.I.; Marchenkov, V.V.; Semisotnov, G.V. 1999: Monomeric form of the molecular chaperone GroEL: structure, stability, and oligomerization Bioorganicheskaia Khimiia 25(5): 358-364
Wiest, D.L.; Burgess, W.H.; McKean, D.; Kearse, K.P.; Singer, A. 1995: The molecular chaperone calnexin is expressed on the surface of immature thymocytes in association with clonotype-independent CD3 complexes EMBO Journal 14(14): 3425-3433
Chen, Y.; Song, J. 1997: Closely relationship between expression of endoplasmic reticulum molecular chaperone Grp94 and c-myc oncogene in human colorectal carcinoma cell lines Zhonghua Zhong Liu Za Zhi 19(2): 81-84
Ronco, P.M. 1992: Should idiopathic extramembranous glomerulonephritis be treated? Toward a "molecular" approach of therapeutic indications Nephrologie 13(5): 189-191
Eguchi, T.; Tezuka, T.; Miyoshi, S.; Yamanashi, Y. 2017: Molecular mechanisms underlying the formation and maintenance of neuromuscular junctions and a possible therapeutic approach Clinical Calcium 27(3): 413-419
Guzhova, I.V.; Novoselov, S.S.; Margulis, B.A. 2005: Hsp70 chaperone and the prospects of its application in anticancer therapy Tsitologiia 47(3): 187-199
Tsuji, D.; Itoh, K. 2007: Molecular pathogenesis and therapeutic targets of lysosomal diseases Seikagaku. Journal of Japanese Biochemical Society 79(7): 678-682
Crouzel, G.; Miani, J.A.; Zelasco, J.F. 1971: Liver diseases and potassium. A new therapeutic approach. Preliminary report Prensa Medica Argentina 58(23): 1201-1206
Leichtman, A.B.; Strom, T.B. 1988: Therapeutic approach to renal transplantation: triple therapy and beyond Transplantation Proceedings 20(6 Suppl 8: 1-6
Perlès, R. 1974: Biochemical diagnosis and therapy of molecular diseases Annales Pharmaceutiques Francaises 32(2): 155-170
Lakatos, P.L.; Lakatos, L.; Pár, A.; Papp, J. 2001: Molecular genetics and gene therapy in diseases of the esophagus, stomach, colon and pancreas Orvosi Hetilap 142(52): 2883-2891
Charria-Ortiz, G.A. 2006: Paroxysmal neurogenetic and neurometabolic disorders Revista de Neurologia 42(Suppl 3): S83-S90
Razumov, A.N.; Namsaraeva, G.T. 2010: On the methodological approach to the elucidation of mechanisms underlying therapeutic effectiveness of Cigun, Indian and Tibetan Yoga therapy Voprosy Kurortologii Fizioterapii i Lechebnoi Fizicheskoi Kultury 1: 39-42
Martić, V. 1997: Modern approach to therapy of emergency conditions in neuromuscular diseases Vojnosanitetski Pregled 54(4): 379-383
Sergeeva, V.A.; Zakharova, N.I.; Sakharova, N.F.; Mordasova, L.A.; Chizhov, B.V. 1989: The use of therapeutic swimming in the combined therapy of children with different diseases in the hospital Voprosy Kurortologii Fizioterapii i Lechebnoi Fizicheskoi Kultury 3: 66-68
Anichini, A.; Cascinelli, N. 2000: Stem cells research: impact on molecular biology of cancer and prospects for therapy of neoplastic diseases Tumori 86(5): 375-380
Herber, D.L. 2007: Molecular Targets in Cancer Therapy - Fourth Biennial Meeting. Mechanism and therapeutic reversal of immune suppression in cancer IDrugs: the investigational drugs journal 10(4): 227-229
Klitgaard, T.Lykke.S.; Haamann, P.H.; Villumsen, Jørgen.E.; Larsen, M. 2005: Intravitreal triamcinolone therapy. New therapeutic alternative for patients with vision-threatening eye diseases Ugeskrift for Laeger 167(16): 1729-1731